Low-dose interleukin-2 for recurrent early pregnancy loss: a proof-of-concept study

BackgroundRegulatory T cells (Tregs) are essential for maternal-fetal tolerance, and their deficiency has been implicated in immune-mediated pregnancy loss. Low-dose interleukin-2 (IL-2LD) selectively expands and activates Tregs and has shown efficacy in murine models of spontaneous immune-mediated miscarriage. This proof-of-concept study assessed the safety and efficacy of IL-2LD in women with unexplained recurrent early pregnancy loss (uREPL). MethodsIn the FACIL-2 open-label trial (NCT03970954), 15 women with [&ge;]5 prior uREPLs received 3 MIU/day of IL-2 for 5 days per cycle, starting 10 days after menses onset. Up to five cycles were administered if pregnancy was not achieved. Treg frequency was measured by flow cytometry, and clinical outcomes were recorded. An additional 9 patients with similar profiles were treated under compassionate use without immunomonitoring. ResultsIn FACIL-2 participants, IL-2LD significantly increased circulating Tregs, with a mean 2.0-fold rise at day-8 (p<0.001), primary endpoint reached) and a sustained elevation at day-29. Among the eight pregnancies, four were viable at 12 weeks, resulting in three live births and one late miscarriage at 20 weeks. Successful pregnancies were associated with greater Treg expansion (day-0 to day-8: 2.87 vs. 1.64-fold, p=0.03; day-0 to day-29: 1.71 vs. 1.24-fold, p=0.008). In the compassionate group, five pregnancies yielded two live births. All newborns were healthy. Safety signals were generally mild and manageable. InterpretationIL-2LD safely expanded Tregs and achieved a 46% rate of viable pregnancies in a high-risk population, and despite the short treatment duration. These results support the further investigation of IL-2LD as an immunotherapy for uREPL in a controlled trial with extended treatment through early gestation.